Literature DB >> 20686504

Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.

A Gessner1, M Thomas, P Garrido Castro, L Büchler, A Scholz, T H Brümmendorf, N Martinez Soria, J Vormoor, J Greil, O Heidenreich.   

Abstract

MLL/AF4 and AML/MTG8 represent two leukemic fusion genes, which are most frequently found in infant acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), respectively. We examined the influence of MLL/AF4 and AML1/MTG8 fusion genes on the expression of TERT coding for the telomerase protein subunit, and subsequently telomerase activity in t(4;11)-positive ALL and t(8;21)-positive cell lines, respectively. MLL/AF4 suppression diminished telomerase activity and expression of TERT. Blocking pro-apoptotic caspase activation in conjunction with MLL/AF4 knockdown enhanced the inhibition of TERT gene expression, which suggests that MLL/AF4 depletion does not reduce TERT expression levels by inducing apoptosis. Knockdown of HOXA7, a direct transcriptional target of MLL/AF4 fusion gene, caused a reduction of telomerase and TERT to an extent similar to that observed with MLL/AF4 suppression. Chromatin immunoprecipitation of SEM cells, using ectopically expressed FLAG-tagged Hoxa7, indicates HOXA7 binding site in the TERT promoter region. Furthermore, suppression of the AML1/MTG8 fusion gene was associated with severely reduced clonogenicity, induction of replicative senescence, impaired TERT expression and accelerated telomere shortening. We thus present findings that show a mechanistic link between leukemic fusion proteins, essential for development and maintenance of leukemia, and telomerase, a key element of both normal and malignant self-renewal.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686504     DOI: 10.1038/leu.2010.155

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

Review 1.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

2.  Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Huining Kang; Carla S Wilson; Richard C Harvey; I-Ming Chen; Maurice H Murphy; Susan R Atlas; Edward J Bedrick; Meenakshi Devidas; Andrew J Carroll; Blaine W Robinson; Ronald W Stam; Maria G Valsecchi; Rob Pieters; Nyla A Heerema; Joanne M Hilden; Carolyn A Felix; Gregory H Reaman; Bruce Camitta; Naomi Winick; William L Carroll; ZoAnn E Dreyer; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

3.  The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.

Authors:  P Garrido Castro; E H J van Roon; S S Pinhanços; L Trentin; P Schneider; M Kerstjens; G Te Kronnie; O Heidenreich; R Pieters; R W Stam
Journal:  Leukemia       Date:  2017-07-10       Impact factor: 11.528

Review 4.  Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Authors:  Ashwin Kishtagari; Justin Watts
Journal:  Ther Adv Hematol       Date:  2017-10-06

5.  Pushing the limits: defeating leukemia stem cells by depleting telomerase.

Authors:  Ya-Huei Kuo; Ravi Bhatia
Journal:  Cell Stem Cell       Date:  2014-12-04       Impact factor: 24.633

6.  Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Authors:  Claudia Bruedigam; Frederik O Bagger; Florian H Heidel; Catherine Paine Kuhn; Solene Guignes; Axia Song; Rebecca Austin; Therese Vu; Erwin Lee; Sarbjit Riyat; Andrew S Moore; Richard B Lock; Lars Bullinger; Geoffrey R Hill; Scott A Armstrong; David A Williams; Steven W Lane
Journal:  Cell Stem Cell       Date:  2014-12-04       Impact factor: 24.633

7.  Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.

Authors:  A Ptasinska; S A Assi; D Mannari; S R James; D Williamson; J Dunne; M Hoogenkamp; M Wu; M Care; H McNeill; P Cauchy; M Cullen; R M Tooze; D G Tenen; B D Young; P N Cockerill; D R Westhead; O Heidenreich; C Bonifer
Journal:  Leukemia       Date:  2012-02-20       Impact factor: 11.528

8.  Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia.

Authors:  F Marchesi; K Girardi; G Avvisati
Journal:  Adv Hematol       Date:  2011-11-15

9.  Pontin is a critical regulator for AML1-ETO-induced leukemia.

Authors:  O Breig; S Bras; N Martinez Soria; D Osman; O Heidenreich; M Haenlin; L Waltzer
Journal:  Leukemia       Date:  2013-12-17       Impact factor: 11.528

10.  Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations.

Authors:  Klaus Rehe; Kerrie Wilson; Simon Bomken; Daniel Williamson; Julie Irving; Monique L den Boer; Martin Stanulla; Martin Schrappe; Andrew G Hall; Olaf Heidenreich; Josef Vormoor
Journal:  EMBO Mol Med       Date:  2012-12-11       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.